2024年12月，任瑞宝研究员/王升跃研究员/李军民主任医师团队在《Signal Transduction and Targeted Therapy》【IF40.8，Q1】杂志发表题为“A phase 2 pilot study of umbilical cord blood infusion as an adjuvant consolidation therapy in elderly patients with acute myeloid leukemia.”——脐带血输注辅助巩固治疗老年急性髓细胞白血病的研究论文。
瑞金医院上海血液研究所/衰老与肿瘤国际研究中心主任任瑞宝研究员、瑞金医院国家转化医学中心（上海）王升跃研究员、瑞金医院血液科李军民主任医师为论文的共同通讯作者；瑞金医院国家转化医学中心（上海）王金增博士、瑞金医院血液科李啸扬副主任医师、瑞金医院上海血液研究所刘萍研究员为论文的共同第一作者。
doi：0.1038/s41392-024-02065-y.
Abstract
Acute myeloid leukemia (AML) is an aging-related malignancy, with patients aged ≥60 years old facing significantly poorer prognosis. Umbilical cord blood (UCB) has emerged as a promising source with effective anti-aging roles. Here, we conducted a prospective, phase 2, single-arm trial of UCB infusion as an adjuvant consolidation therapy in elderly AML patients (ChiCTR-OPC-15006492). A total of 51 patients were enrolled (median age 66 years; range, 60–75) and received two cycles of consolidation chemotherapy combined with UCB infusion. At a median follow-up of 27.3 months (range, 9.3–100), the median overall survival (OS) was not yet reached and the median event-free survival (EFS) was 72.2 months (range, 5.4–100). The 2-year OS and EFS rates were 76.9% and 62.8%, respectively. No acute graft-versus-host disease (aGVHD) or toxicity-related death occurred in any patient. The median times to platelet and neutrophil recovery were 11.5 days (range, 6–17) and 12.2 days (range, 0–21), respectively. Single-cell RNA sequencing (scRNA-seq) identified enhanced anti-tumor and anti-aging properties of UCB, manifested through activation of immune responses and telomere synthesis/maintenance. These findings suggest that UCB infusion is an effective and safe post-remission adjuvant therapy for elderly AML patients. This study provides evidence that anti-aging therapy may serve as a new and promising dimension in combined cancer treatment.
中文摘要
作者介绍
任瑞宝 研究员、博士生导师，上海交通大学医学院附属瑞金医院/上海市血液学研究所、组学与疾病全国重点实验室、衰老与肿瘤国际研究中心主任，国家特聘专家，上海交通大学“王宽诚”讲席教授；血液与肿瘤学杂志（JHO）及衰老与肿瘤杂志（Aging and Cancer）副主编；研究方向：血液系统衰老、白血病分子机制及靶向治疗研究。
王升跃 研究员，博士生导师，上海交通大学医学院附属瑞金医院/上海血液学研究所、组学与疾病全国重点实验室、国家转化医学中心（上海）；研究方向：基因组学、功能基因组学和表观基因组学研究。
李军民 主任医师，博士生导师，上海交通大学医学院附属瑞金医院/上海血液学研究所、组学与疾病全国重点实验室、血液科；研究方向：血液系统恶性肿瘤的发病机制及临床治疗、肿瘤相关治疗性疫苗的研发。
王金增 博士，上海交通大学医学院附属瑞金医院/上海血液学研究所、组学与疾病全国重点实验室、国家转化医学中心（上海）；研究方向：生物信息学、衰老和癌症与转化医学研究、白血病发病机制及靶向治疗研究。
李啸扬 副主任医师，上海交通大学医学院附属瑞金医院/上海血液学研究所、组学与疾病全国重点实验室、血液科；研究方向：白血病发病机制及靶向治疗研究。
刘萍 研究员，上海交通大学医学院附属瑞金医院/上海血液学研究所、组学与疾病全国重点实验室；研究方向：造血调控、白血病发病机制及靶向治疗研究。
【扫描二维码可下载原文】
A phase 2 pilot study of umbilical cord blood infusion as an adjuvant consolidation therapy in elderly patients with acute myeloid leukemia.pdf
